SecBot SecBot

DSGN

Design Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001807120 Biotech & Drug Discovery
$10.38 +0.14 (+1.37%)
Oct 26 4:00 PM ET · prev $10.24
Market cap
$656.5M
Small cap
Consensus
Buy
92% Buy or better · 13 analysts
Median target
$21.00
+102% · range $20.00–26.00
Next earnings
Nov 11
in 16 days · EPS est. −$0.35
1 year
+48.9%
from $6.97 · Oct 27
30 days
−16.0%
from $12.36
52-week range
$6.24–15.94
−35% from high · low Nov 4
Avg volume 20D
505.1K
shares / day
Short interest
6.62M
≈10.6% of shares · +21.1%
Days to cover
8.7
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 1 exit
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 1 bullish · 1 mixed oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 11, 2026
Strongest MIXED Design Therapeutics reported Q2 2026 financial results with a net loss of $20.2M ($0.32 per share), beating…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 30 added (0 new), 15 trimmed or exited.

  • AnalystsBULLISH

    12 of 13 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.359 → −$0.346 over 90 days. 2 up, 1 down in 30 days.

  • Short sellersBUILDING

    Short interest +21.1% to 6.62M shares. 8.7 days to cover, ≈10.6% of shares.

  • TrendDOWNTREND

    20% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
1
exit
FundMoveSharesValue
DRIEHAUS CAPITAL MANAGEMENT LLCADD2,661,115$38.5M
Caption Management, LLCDOUBLED1,118,098$16.2M
GEODE CAPITAL MANAGEMENT, LLCADD958,417$13.9M
Woodline Partners LPTRIM700,354$10.1M
DIMENSIONAL FUND ADVISORS LPADD694,743$10.1M
GOLDMAN SACHS GROUP INCADD656,584$9.5M
JACOBS LEVY EQUITY MANAGEMENT, INCADD565,597$8.2M
Qube Research & Technologies LtdDOUBLED437,079$6.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 92% rate it Buy or better
Strong Buy5Buy7Hold1Sell0Strong Sell0
12-month targets · 7 analysts

Price is below the lowest target. Median implies +102%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 2, 2026Wells Fargo
INITIATE
INITIATEOverweight
May 4, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 9, 2026
Berger Heather A.
Director
AWARD30,000 sh
Jun 9, 2026
Gover Justin D.
Director
AWARD30,000 sh
Jun 9, 2026
Shapiro David
Director
AWARD30,000 sh
Jun 9, 2026
LAPPE RODNEY W
Director
AWARD30,000 sh
Jun 9, 2026
Schmid John P.
Director
AWARD30,000 sh
Jun 9, 2026
George Simeon
Director
AWARD30,000 sh
Mar 31, 2026
Shapiro David
Director
AWARD7,500 sh
Mar 31, 2026
Shapiro David
Director
AWARD60,000 sh

Earnings setup

Estimates
Nov 11
reports in 16 days
−$0.35
EPS estimate, this quarter
+3%
estimate change, 90 days
2↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.35-$0.39–-$0.30+1.9%$0.00
Next Q-$0.39-$0.62–-$0.29+2.1%$0.00
Current FY-$1.35-$1.63–-$1.23+1.1%$0.00
Next FY-$1.62-$2.04–-$1.17-1.6%$0.00

Short side

FINRA· Sep 30, 2026
6,616,513
shares short
+21.1%
vs prior settlement
8.7
days to cover
≈10.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 Short interest report
Short Interest: DSGN up 21% to 6.6M shares
Settlement 2026-09-30 | Days to cover: 8.69 | ≈10.57% of shares outstanding (est.)
Aug 3, 2026 SEC
Design Therapeutics reported Q2 2026 financial results with a net loss of $20.2M ($0.32 per share), beating consensus…
8-K — Impact 5/10
Aug 3, 2026 SEC
Design Therapeutics reported Q2 2026 net loss of $0.32 per share, beating consensus of -$0.36 by 11%, and highlighted…
PRESS-RELEASE — Impact 5/10
Jun 30, 2026 Inst.
DRIEHAUS CAPITAL MANAGEMENT LLC — ADD
2,661,115 shares ($38.5M)
Jun 30, 2026 Inst.
Caption Management, LLC — DOUBLED
1,118,098 shares ($16.2M)
Jun 9, 2026 Insider
Berger Heather A. was granted 30,000 shares
Director
Jun 9, 2026 Insider
Gover Justin D. was granted 30,000 shares
Director
Jun 9, 2026 Insider
Shapiro David was granted 30,000 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
DSGN Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Sep 30, 2026
Short interest
Short Interest: DSGN up 21% to 6.6M shares
Settlement 2026-09-30 | Days to cover: 8.69 | ≈10.57% of shares outstanding (est.)
Aug 10, 2026
Earnings date
DSGN Q2 2026 Earnings Scheduled — 2026-08-10
Aug 5, 2026
Earnings date
DSGN Q2 2026 Earnings Scheduled — 2026-08-05
Aug 3, 2026
Earnings
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027
Jun 30, 2026
Short interest
Short Interest: DSGN up 23% to 5.7M shares
Settlement 2026-06-30 | Days to cover: 5.16 | ≈9.15% of shares outstanding (est.)

SecBot reports

6 filings · 2 press releases · 3 bullish · 0 bearish · 1 mixed · 2 neutral
All DSGN filing & press-release reports (8)